Table of novel agents targeting migration and adhesion.

Pathway or Target	Therapeutic agent	Clinical or preclinical testing	Reference
CXCR4	Plerixafor	Preclinical testing	43
VLA-4 and LFA-1	VLA-4 antibodies	Preclinical testing	43
Src	AZD0530	Preclinical testing	45
PI3K/Akt/mTOR pathway	Perifosine, RAD001, BEZ-235	○ Phase II trial of perifosine showed an ORR of 35% including MR in relapsed or refractory WM. ○ Phase II trial of RAD001 showed an ORR of 70% including MR in relapsed or refractory WM. ○ NVP-BEZ-235 completed preclinical testing.	56, 57, 58, 59,
NF-kB	Bortezomib, NPI-0052, carfilzomib and Onyx 0912	○ Bortezomib single agent or in combination with rituximab has completed phase II clinical trials in WM with an ORR of about 80-90% including MR in newly diagnosed or relapsed WM. ○ NPI-0052, Carfilzomib and Onyx-0912 completed preclinical testing.	61-65
miRNA	Anti-miR-155 LNA	Preclinical testing	66